Skip to main content

Table 1 Baseline characteristics

From: Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome – a prospective randomized double-blind clinical trial

 

Group 1 (n = 26)

Group 2 (n = 31)

P-value

Age

31.3 ± 3.3

32.2 ± 3.4

0.31

Parity (n)

0.1 ± 0.4

0.1 ± 0.4

0.94

BMI (kg/m2)

26.3 ± 4.8

27.4 ± 5.5

0.40

Antral follicle count (n)

22.2 ± 7.8

24.3 ± 12.4

0.48

Antral follicle count > 12 (n, %)

24/26 (92.3)

24/31 (77.4)

0.12

AMH (ng/ml)

8.3 ± 5.8

8.4 ± 4.9

0.98

AMH > 3.5 (n, %)

23/26 (88.5)

30/31 (96.8)

0.22

Baseline serum FSH (IU/L)

5.6 ± 1.7

5.2 ± 1.6

0.39

PCOS (n, %)

8/26 (30.8)

8/31 (25.8)

0.67

Primary cause of infertility (n, %)

  

0.22

 Anovulation

20/26 (76.9)

18/31 (58.1)

 

 Male Factor

3/26 (11.5)

2/31 (6.5)

 

 Tubal disease

1/26 (3.8)

2/31 (6.5)

 

 Unexplained

1/26 (3.8)

8/31 (25.8)

 

 Others

1/26 (3.8)

1/31 (3.2)